Core Viewpoint - The chronic heart failure (CHF) new drug market is a blue ocean with significant unmet medical needs and high potential returns on investment due to the increasing prevalence of heart failure patients and the inadequacy of current treatment options [2][6][21]. Group 1: Chronic Heart Failure Market Overview - Heart failure is a serious clinical syndrome characterized by high morbidity and mortality, with approximately 13.7 million patients in China and a rising prevalence [2][6]. - The current treatment options for heart failure show poor prognosis, with high rates of readmission and mortality [7][21]. Group 2: Investment Potential in CHF Drug Development - The development of new drugs for chronic heart failure is a high-investment, high-return business, with only four innovative drugs approved globally in the past 30 years [2][8]. - The existing drugs for heart failure, such as ARNI, SGLT2 inhibitors, and sGC, have shown significant clinical benefits, indicating a strong market potential for new entrants [9][12][21]. Group 3: Key Players and Innovations - The NRG-1/ErbB pathway is highlighted as a promising target for new heart failure treatments, with products like JK07 showing potential to address limitations of existing therapies [23][25]. - Current leading drugs include Novartis' Entresto (ARNI), which is projected to achieve global sales of approximately $7.82 billion in 2024, and SGLT2 inhibitors like Dapagliflozin and Empagliflozin, which are also expected to contribute significantly to sales [21][22]. Group 4: Clinical Challenges and R&D Barriers - The clinical development of heart failure drugs faces high risks in early-stage exploration and significant challenges in late-stage clinical design, making it difficult for smaller companies to succeed [15][18][19]. - The complexity of heart failure, including patient heterogeneity and the need for hard endpoints in clinical trials, adds to the difficulty of drug development [17][18].

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-016 江苏恒瑞医药股份有限公司 关于药品临床试验进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）自主研发的羟乙磺 酸达尔西利片联合内分泌治疗在激素受体（HR）阳性、人表皮生长因子受体 2 （HER2）阴性女性乳腺癌辅助治疗中的一项多中心、随机、双盲的Ⅲ期临床试验 （研究方案编号：SHR6390-Ⅲ-303），首次期中分析主要终点达到统计学显著性。 研究结果显示，达尔西利联合内分泌治疗，较安慰剂联合内分泌治疗，可显著降 低患者复发风险，提高患者无侵袭性疾病生存期（IDFS）[1]。公司已于近期向国 家药品监督管理局药品审评中心递交上市前沟通交流申请。 一、 药品的基本情况 药品名称：羟乙磺酸达尔西利片 剂型：片剂 二、 药品的临床试验情况 达尔西利已于国内获批两项适应症，即本品适用于激素受体（HR）阳性、人 表皮生长因子受体 2（HER2）阴性局部晚期或转移性乳腺癌患者：1.与芳香化酶 抑制剂联合使 ...